Emergent Biosolutions (NYSE:EBS) Stock: Insider Paul Anthony Williams Sells 3,000 Shares

Emergent Biosolutions Inc. (NYSE:EBS) SVP Paul Williams sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $6.53, for a total value of $19,590.00. Following the sale, the senior vice president owned 156,098 shares in the company, valued at approximately $1,019,319.94. This represents a 1.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Price Performance

NYSE:EBS opened at $6.93 on Wednesday. Emergent Biosolutions Inc. has a 1-year low of $4.36 and a 1-year high of $14.06. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70. The firm has a fifty day simple moving average of $6.10 and a 200 day simple moving average of $7.47. The stock has a market capitalization of $355.48 million, a PE ratio of -1.95 and a beta of 2.28.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.68. The business had revenue of $234.30 million for the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. On average, research analysts expect that Emergent Biosolutions Inc. will post 0.13 EPS for the current fiscal year.

Institutional Trading of Emergent Biosolutions

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Emergent Biosolutions in the 2nd quarter valued at $39,525,000. Ancora Advisors LLC acquired a new stake in shares of Emergent Biosolutions during the second quarter worth $8,949,000. Palisade Capital Management LP acquired a new stake in shares of Emergent Biosolutions during the second quarter worth $4,316,000. Dimensional Fund Advisors LP boosted its position in shares of Emergent Biosolutions by 22.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock valued at $22,884,000 after acquiring an additional 504,553 shares during the period. Finally, Pacer Advisors Inc. bought a new stake in shares of Emergent Biosolutions in the first quarter valued at about $3,454,000. Institutional investors own 78.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on EBS. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a research note on Friday, August 21st. They issued an “underweight” rating for the company. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research note on Tuesday, August 11th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. Finally, Weiss Ratings raised Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

About Emergent Biosolutions

Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.

Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.